Bioreactor for artificial tissue or organ production and operating method thereof

The supercritical CO2 bioreactor addresses inefficiencies in decellularization and recellularization by enabling continuous, automated processing that preserves the extracellular matrix, resulting in efficient and reproducible production of functional biological tissues.

WO2026234617A1PCT designated stage Publication Date: 2026-11-12UNIVE CATOLICA PORTUGUESA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054535
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing tissue engineering methods for decellularization and recellularization are often time-consuming and inefficient, particularly in batch processes that can damage the extracellular matrix and result in inconsistent outcomes.

Method used

A tailored supercritical CO2 bioreactor for continuous decellularization and recellularization processes, utilizing supercritical CO2 for efficient cellular material removal while preserving the ECM, integrated with automated systems for controlled recellularization.

Benefits of technology

The bioreactor enables efficient, automated, and reproducible production of functional biological tissues by maintaining tissue integrity and improving throughput, minimizing manipulation, and ensuring consistent results through controlled processing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2026054535_12112026_PF_FP_ABST
    Figure IB2026054535_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to a bioreactor and a method for artificial tissue or organ production. The bioreactor comprises at least one reaction chamber designed to receive and process a tissue, fluid inlets and outlets for the controlled inflow and outflow of fluids, and supply means for supercritical CO₂ and biological solutions. The bioreactor enables a sequential process of tissue decellularization using supercritical CO₂, sterilization with a dedicated solution, and recellularization through the introduction of a culture medium and a cell inoculum. An electronic data processor controls and monitors the process, ensuring optimal conditions for scaffold preparation and tissue regeneration. The method involves introducing a tissue into the reaction chamber, decellularizing it with supercritical CO₂ and / or a solution, sterilizing it, and recellularizing the scaffold to produce an artificial tissue or organ. The invention provides a controlled and efficient system for bioengineering applications, ensuring reproducibility and biocompatibility.
Need to check novelty before this filing date? Find Prior Art

Description

D E S C R I P T I O NBIOREACTOR FOR ARTIFICIAL TISSUE OR ORGAN PRODUCTION AND OPERATING METHOD THEREOFTECHNICAL FIELD

[0001] The present disclosure relates to biotechnology and biomedical engineering, particularly to apparatuses and methods for tissue engineering involving decellularization and recellularization processes. The present disclosure relates to a tailored supercritical CO2 bioreactor engineered for the continuous decellularization and recellularization processes, along with its operational method.BACKGROUND

[0002] There are several methods used for decellularization of tissue grafts, each with its own advantages and considerations. Some common methods include, for example, chemical decellularization wherein involves treating the tissue with various chemical agents to remove cellular components while preserving the extracellular matrix (ECM), or perfusion decellularization, which involves perfusing the tissue with decellularization chemical-based solutions through the vasculature to remove cellular components while maintaining the integrity of the tissue structure.

[0003] Nevertheless, combination methods persist, where many decellularization protocols amalgamate various techniques to enhance cell removal while minimizing damage to the ECM. For instance, a blend of enzymatic treatment, followed by physical agitation or perfusion, may be employed to achieve comprehensive decellularization, among other approaches.

[0004] The choice of the decellularization method depends on factors such as the tissue type, desired level of decellularization, preservation of ECM properties, and intended application of the tissue graft. Each method has its own advantages and limitations, and researchers often optimize protocols based on specific requirements for their applications.

[0005] Document W02014110135A1 discloses a bioreactor for large-mammal lung tissue. The bioreactor is capable of hydraulic driven negative-pressure and positivepressure perfusion and ventilation. Perfusion and ventilation are delivered at physiological rates and is easily controllable. In one embodiment, the bioreactor comprises a support scaffold to support the size of a large-mammal lung tissue. In another embodiment, the bioreactor comprises a pleural sack that provides a small isolated fluid chamber which surrounds an engineered lung, thereby minimizing the amount of culture media needed. The present document also provides an in vitro model for examining the function of a test agent and compositions and methods for alleviating a lung defect in a large-mammal.

[0006] Document WO2023066599A1 discloses a bioreactor comprising a reactor chamber for producing a soft tissue, comprising an analysis unit for measuring a number of tissue parameters of the soft tissue, comprising a conditioning unit for conditioning the soft tissue according to a number of process parameters, comprising a control unit which controls the analysis unit and the conditioning unit in such a way that during manufacture the tissue parameters are measured and the process parameters are set depending on the tissue parameters, so that the soft tissue is conditioned depending on the tissue parameters. The recellularization is a dynamic process of seeding cells into the graft, and recipient stem cells can be used for clinical transplantation; the disclosure also relates to a method for operating the bioreactor.

[0007] Document US2022228097A1 discloses a configurable system for repeatably performing processes related to tissue growth in a controlled environment, possibly part of an industrial production line. The system can accommodate various sizes and shapes of culture vessels, and can maintain the cells at a desired temperature in the culture vessels, thus enabling a plug and play system that can produce consistent and repeatable results. The system includes gas management, fluid management, and control of multiple processes simultaneously, and can be automatically operably coupled with a variety of supporting technologies that can enable tissue-related processes. The system can communicate with supporting technologies upstream and downstream on a manufacturing line, enabling fully automated process control, centralized data historization, and centralized control.

[0008] Document CN118272222B discloses a membrane decellularization device, in particular to an apparatus and method for the complete decellularization of amniotic membrane based on bio-enzyme technology. The apparatus is based on bio-enzyme technology and comprises a supercritical carbon dioxide extraction vessel, the inner wall of the bottom of the supercritical carbon dioxide extraction vessel is provided with a socket, into which an enzymatic processing vessel is inserted; the top of the enzymatic processing vessel is fitted with an enzymatic processing vessel lid; a connecting pipe is inserted through the enzymatic processing vessel lid; and an enzymatic processing control valve is installed on the connecting pipe.

[0009] These facts are disclosed in order to illustrate the technical problem addressed by the present disclosure.GENERAL DESCRIPTION

[0010] The field of tissue engineering requires solutions that enable the efficient preparation of decellularized scaffolds that can be subsequently recellularized to produce functional biological tissues. Existing technologies often involve batch processes that are time-consuming and may result in inefficient treatment of tissues.

[0011] One of the goals of the present disclosure, is to provide a bioreactor and a method that can continuously and simultaneous process several tissues through decellularization and recellularization in a controlled, efficient manner.

[0012] The present disclosure addresses the aforementioned challenges by providing a tailored CO2 bioreactor that surprisingly allows the continuous processes of decellularization and recellularization of biological tissues. This reactor utilizes supercritical CO2 for decellularization, effectively removing cellular material without damaging the extracellular matrix. It also features an integrated system for subsequent recellularization. The present solution allows for controlled, automated processing that maintains tissue integrity and improves throughput, all within a fully automated system that minimizes tissue manipulation. During tissue decellularization, maintenance of the native ultrastructure and composition of ECM is extremely acceptable. Forrecellularization, the scaffold / matrix is seeded with cells, the final goal being to form a functional living tissue.

[0013] An aspect of the present disclosure relates to a bioreactor for artificial tissue or organ production, among other applications, comprising:at least one reaction chamber arranged to receive and process a tissue or cellularized material;at least one fluid inlet and at least one fluid outlet connected to the reaction chamber for inflow and outflow of fluids;at least one door for facilitating the placement of the tissue inside the reaction chamber;supercritical CO2 supply means connected to the at least one fluid inlet and the at least on fluid outlet for supplying supercritical CO2 in the reaction chamber for decellularization of the tissue;solution supply means connected to the at least one fluid inlet and the at least on fluid outlet, wherein the solution supply means is configured to supply a culture medium, and / or a cell inoculum in the reaction chamber for recellularization of the tissue;an electronic data processor configured to control and monitor the solution supply means and the supercritical CO2 supply means allowing decellularization, sterilization, drying and / or recellularization of the tissue to obtain an artificial tissue or organ.

[0014] In an embodiment, the solution supply system is configured for recellularization of the tissue by supplying at least one of the following solutions: a cell suspension, a hydrogel containing cells, a growth medium, a differentiation medium, cell spheroids, cell organoids or a combination thereof to the interior of the reaction chamber.

[0015] In an embodiment, the solution supply system is further configured for decellularization of the tissue in the reaction chamber by supplying at least one of the following solutions: a decellularization solution, or a combination thereof; preferably ultrapure water, an enzymatic solution, a detergent solution, an acid or alkaline solution, a chelating agent solution, or a combination thereof.

[0016] In an embodiment, the solution supply system is further configured for sterilization of the tissue in the reaction chamber by supplying at least one of the following solutions: a sterilization solution, or a combination thereof; preferably ethanol, isopropanol, peracetic acid solution, hydrogen peroxide solution, antibiotic and / or antimycotic solution, supercritical CO2 combined with a sterilizing additive, or a combination thereof.

[0017] In an embodiment, the bioreactor comprises drying means for removing residual moisture and solvents from the tissue.

[0018] In an embodiment, the bioreactor comprises comprising a residue outlet for discharging cellular debris, chemical residues, and byproducts generated during decellularization, sterilization, drying and / or recellularization; preferably wherein the residue outlet is operatively connected to a filtration system for facilitating efficient removal and preventing contamination.

[0019] In an embodiment the bioreactor further comprises:a CO2 reservoir (or tank) and;a CO2 pump arranged to compress liquid CO2 into a supercritical state for pressurizing the reaction chamber and facilitating the removal of biological content from the tissue content.

[0020] In an embodiment, the supercritical CO2 supply means further comprise a CO2 input valve and CO2 output valve for controlling inflow and outflow of supercritical CO2 to the interior of the reaction chamber.

[0021] In an embodiment, the supercritical CO2 supply means comprise a mass flow meter for measuring and control of supercritical CO2 entering the CO2 pump.

[0022] In an embodiment the bioreactor further comprises:at least one solution reservoir (or tank), preferably 2, 3, 4 or 5 solution reservoirs; and,a solution pump for circulating a solution between said at least one solution reservoir and an interior of the reaction chamber.

[0023] In an embodiment, each of the at least one solution reservoir (or tank) of the solution supply means further comprises a solution input valve and a solution output valve for controlling inflow and outflow of solution to the interior of the reaction chamber.

[0024] In an embodiment, the bioreactor further comprises heating means surrounding a main body of the reaction chamber, wherein said heating means are configured to regulate and maintain the temperature inside the reaction chamber.

[0025] In an embodiment, the bioreactor further comprises a temperature probe for measuring temperature in the interior of the reaction chamber.

[0026] In an embodiment, the bioreactor further comprises a rotative stirrer placed under a tissue support wherein the tissue is placed upon said tissue support, wherein the rotative stirrer is arranged for promoting mass changes between tissue cells.

[0027] In an embodiment, the bioreactor further comprises a volumetric stirrer f luidica lly connected to the outlet fluid connection and to the inlet fluid connection; and configured to displace the solution within the reaction chamber in one direction or the opposite.

[0028] In an embodiment, the bioreactor further comprises a back pressure regulator operatively connected to the at least one outlet fluid connection for controlling a maximum pressure in the interior of the reaction chamber.

[0029] In an embodiment, the electronic data processor is configured to regulate the back pressure regulator, preferably for setting a maximum allowable pressure within the reaction chamber.

[0030] In an embodiment, the bioreactor comprises a one-way valve operatively connected to the at least one inlet fluid connection for preventing back-flow of fluids going into the interior of the reaction chamber.

[0031] In an embodiment, the bioreactor comprises a volumetric actuator operatively connected to the input fluid connection upstream of the one-way valve, for allowing pressure changes within the interior of the reaction chamber.

[0032] In an embodiment, the electronic data processor is configured to control an internal volume of the volumetric actuator for allowing pressure changes within the interior of the reaction chamber.

[0033] In an embodiment, the bioreactor comprises at least one door for facilitating the placement of the tissue inside the reaction chamber.

[0034] In a further embodiment, the bioreactor comprises:at least one visualization window;at least one illumination window; whereinthe at least one visualization window and the at least one illumination window are disposed on the at least one door; or integrated into an outer body of the reactor to provide in situ visual access to the interior of the chamber.

[0035] In an embodiment, the bioreactor comprises a perfusion port for accommodating the insertion of a needle or syringe for direct access to the tissue; preferably the perfusion port further comprising a ball valve for enabling rapid repressurization of the reaction chamber.

[0036] In an embodiment, the bioreactor comprises a plurality of reaction chambers, preferably 2, 3, 4, 5 reaction chambers, for enabling simultaneous execution of different cycles of decellularization, sterilization, drying, and recellularization wherein each reaction chamber comprises its own solution supply means to avoid crosscontamination between chambers.

[0037] In an embodiment, the bioreactor comprises at least one of the following sensors: temperature sensor, nutrient sensor, pressure sensor, flow sensor, anti-foam sensor, pH sensor, 02 sensor, CO2sensor, or combinations thereof; wherein the electronic data processor is configured to control temperature, air flow, nutrient flow, anti-foam flow, pH tuning, 02 flow, supercritical CO2flow, or combinations thereof.

[0038] A further aspect of the present disclosure relates to a method of operating a bioreactor for artificial tissue or organ production according to any of the previous claims, comprising the following steps (preferably in the following order):introducing the tissue into the at least one reaction chamber;supplying supercritical C02and / or at least one decellularization solution into the interior of the reaction chamber for decellularizing the biological content of the tissue in other to obtain a scaffold;introducing a sterilization solution in the reaction chamber for ensuring the elimination of contaminants before recellularization;feeding the reaction chamber with a cell inoculum and a culture medium for the recellularization of the scaffold and generate an artificial tissue or organ.

[0039] In an embodiment, the method comprises the step of removing excess material from the reaction chamber after decellularization, sterilization, drying and / or recellularization, wherein the excess material includes residual cellular debris, unreacted solutions, and / or processing byproducts.

[0040] In an embodiment, the method comprises the step of drying the scaffold after decellularization, sterilization, drying and / or recellularization.BRIEF DESCRIPTION OF THE DRAWINGS

[0041] The following figures provide preferred embodiments for illustrating the disclosure and should not be seen as limiting the scope of the disclosure.

[0042] Figure 1: Schematic diagram representation of a reaction chamber according to an embodiment of the present disclosure. The elements shown include:6- a reaction chamber;7- a temperature probe;8- a door of the reaction chamber;9- a visualization window;10- an illumination window;11- an outlet fluid connection;12- a tissue;13- a perfusion port;14- a Ball valve;15- a tissue support;16- heating means;17- a rotative stirrer; and18- an inlet fluid connection;

[0043] Figure 2: Schematic diagram representation of the reaction chamber depicting external connecting elements, according to an embodiment of the present disclosure. The additional elements shown include:19- a volumetric actuator;20- a one-way valve; and21- a back pressure regulator (BRP);

[0044] Figure 3: Schematic diagram representation of the reaction chamber depicting external connecting elements, in particular the connection to a volumetric stirrer, in accordance to an embodiment of the present disclosure. The additional element shown being:22- the volumetric stirrer;

[0045] Figure 4: Schematic diagram representation of the reaction chamber depicting external connecting elements, in particular showing the solution supply means with a single pump and the super critical carbon dioxide supply means, in accordance to an embodiment of the present disclosure. The additional elements shown being:23- solution supply means;23.1- solution reservoir(s) or tank(s);23.2- solution pump;23.3- solution input valve(s);23.4- solution output valve24- scCOz supply means;24.1- CO2reservoir (or tank);24.2- mass flow meter (MFM);24.3- CO2pump;24.4- CO2 input valve;24.5- CO2 output valve

[0046] Figure 5: Schematic diagram representation of the reaction chamber depicting external connecting elements, in particular depicting the solution supply means in a configuration with multiple pumps and the super critical carbon dioxide supply means, in accordance to an embodiment of the present disclosure.

[0047] Figure 6: Schematic diagram representation of an embodiment of the present disclosure comprising several reaction chambers sharing the same scCO2supply means.

[0048] Figure 7: Generic schematic representation of tissue processing within the bioreactor according to the present disclosure. The elements shown include:6- the reactor chamber;25- a dECM (decellularized Extracellular Matrix);26- a rECM (recellularized Extracellular Matrix);

[0049] Figure 8: Flowchart illustrating the main steps of the method for operating a bioreactor, including tissue introduction, decellularization, sterilization, and recellularization to produce an artificial tissue or organ.

[0050] Figure 9: Schematic representation of an embodiment of a decellularization method:27- Collection of the porcine pancreas body;28- Thawing of pancreatic tissue in PBS_Chl;29- Standardized sectioning of pancreatic tissue samples;30- Cold incubation of tissue sections under agitation;31- Traditional detergent-based decellularization protocol (T_dECM);31.1- Initial washing with PBS_Chl or UPw_Chl;31.2- Cell membrane disruption with 0.5% (w / v) SDC;31.3- Detergent treatment with 0.1% (v / v) Triton X-100;31.4- Enzymatic digestion of residual nucleic acids with DNase (40 lU / mL);31.5- Final washing with PBS_Chl or UPw_Chl;32- Supercritical CO2-based decellularization protocol (scCO2_dECM);32.1- Washing of pancreatic sections with PBS before scCO2exposure; 32.2- Supercritical CO2decellularization cycle;32.3- Sequential post-scCO2washing with UPw and PBS_Chl.

[0051] Figure 10: Graphical representations of an embodiment of biochemical characterization of native and decellularized porcine pancreatic tissue.

[0052] Figure 11: Graphical and microscopic representations of an embodiment of structural characterization of native and decellularized porcine pancreatic tissue.

[0053] Figure 12: Graphical representations of an embodiment of biochemical and proteomic characterization of native and decellularized porcine pancreatic tissue.

[0054] Figure 13: Graphical representations of an embodiment of sterilization validation and endotoxin quantification of decellularized porcine pancreatic matrices.

[0055] Figure 14: Graphical and microscopic representations of an embodiment of in vitro biological assessment of decellularized porcine pancreatic matrices.DETAILED DESCRIPTION

[0056] The present disclosure relates to a bioreactor and correspondent method of operating, tailored for continuous decellularization and recellularization of biological tissues, including a reaction chamber suitable for supercritical CO2, integrated modules for decellularization and recellularization, and a specific control system. This solution improves on existing processing methods by allowing continuous, automated processing, thereby enhancing the efficiency and uniformity of tissue obtained.

[0057] The bioreactor comprises at least one reaction chamber designed to receive and process a tissue, fluid inlets and outlets for the controlled inflow and outflow of fluids, and supply means for supercritical CO2and biological solutions. The bioreactor enables a sequential process of tissue decellularization using supercritical CO2, sterilization witha dedicated solution, and recellularization through the introduction of a culture medium and a cell inoculum. An electronic data processor controls and monitors the process, ensuring optimal conditions for scaffold preparation and tissue regeneration. The method involves introducing a tissue into the reaction chamber, decellularizing it with supercritical CO2and / or a solution, sterilizing it, and recellularizing the scaffold to produce an artificial tissue or organ. The invention provides a controlled and efficient system for bioengineering applications, ensuring reproducibility and biocompatibility.

[0058] Referring now to Figures 1-6, which illustrate schematic diagrams of the reaction chamber in the bioreactor according to a preferred embodiment of the present disclosure, a detailed description of the main components of the reactor chamber and its connecting elements is provided below.

[0059] A reaction chamber 6 for decellularization, sterilization, drying and recellularization of a generic tissue 12 is depicted in detail in the diagrams of Figures 1-5. The reaction chamber is designed to withstand pressures of up to 60 MPa. The tissue 12 is placed into a tissue support 15. A rotative stirrer 17 is also placed under the tissue support, whose function is to stir the liquid medium (i.e. the solution) promoting the arrival of said solution into the proximity of the tissue and facilitating its interaction with the cells. Preferably, the rotative stirrer is actuated via a magnetic coupling, ensuring efficient and contamination-free operation. Alternatively, or additionally, the reaction chamber also comprises a volumetric stirrer 22 with alternating movement, which promotes mass flow between two spaced-apart regions (i.e. from a fluid inlet 18 and a fluid outlet 11), further improving the agitation and distribution of the liquid medium.

[0060] In an embodiment, the bioreactor also comprises a temperature probe 7, operatively positioned to measure the temperature within the reaction chamber, thereby enabling precise monitoring and with heating means control of the reaction environment. The reactor further includes at least one door 8, configured to facilitate the placement of tissue inside the reaction chamber. Additionally, the reactor is equipped with at least one visualization window 9 and at least one illumination window 10, which may be disposed on the door 8 or integrated into the outer body of the reactor to provide in situ visual access to the interior of the chamber.

[0061] In an embodiment, a perfusion port 13 is provided, which incorporates a ball valve 14, to enable rapid re-pressurization of the chamber when required. The perfusion port 13 is configured to accommodate the insertion of a needle or syringe for the direct introduction or "feeding" of solution onto the tissue, particularly when the reaction chamber is either not pressurized or maintained at low pressure. Preferably, this port is oriented towards the area of the reaction chamber where the tissue is located, allowing the cells to be deposited as directly as possible onto the tissue. It is recognized that, in a first approach, the needle will be straight and rigid. To utilize the perfusion port 13, the reaction chamber must first be depressurized, following which the ball valve 14 is positioned in the open state. It should be noted that alternative types of valves may also be employed without departing from the scope of the invention.

[0062] Elements 18 and 11 correspond to at least one inlet fluid connection and at least one outlet fluid connection, respectively, configured to facilitate the inflow or outflow of at least one solution, scCO2, or other suitable fluids into or out of the reaction chamber. These fluid connections are designed to enable controlled fluid transfer, ensuring proper operation and adaptability of the reaction chamber for various processes and conditions.

[0063] Heating means 16 are operatively associated with and surround the main body of the reaction chamber, configured to regulate and maintain the temperature within the specified process parameters. The heating means are designed to control temperatures typically ranging from 25°C to 120°C, and more particularly from 30°C to 40°C, thereby ensuring optimal thermal conditions for the process.

[0064] In Figure 2, further connecting elements are depicted, namely a volumetric actuator 19, a one-way valve 20, and a back pressure regulator (BRP) 21. The BRP 21 establishes the maximum allowable pressure within the reaction chamber, thereby controlling the inlet pressure while permitting any excess pressure to be vented out through the regulator. The volumetric actuator 19 enables the reduction of pressure below the maximum pressure set by the BRP 21 by allowing a controlled increase in the internal volume of the reaction chamber.

[0065] In an embodiment of the bioreactor as depicted in Figure 3, and as previously mentioned, an additional stirrer is included, specifically a volumetric stirrer 22. This stirrer, such as a volumetric piston stirrer, is configured to displace the liquid within the reaction chamber in one direction or the opposite, thereby enhancing mixing and ensuring uniform distribution of the fluid.

[0066] Figure 4 further shows, in an embodiment, solution supply means 23 and its integration within the reactor. Said solution supply means 23 include at least one solution reservoir (or tank) 23.1, a solution pump 23.2, and at least one respective solution input valve 23.3 and output valve 23.4. The reservoirs (or tanks) labeled A to n in Figures 5-7 refer to the referenced at least one solution reservoir (or tank) (A to n reservoirs or tanks, this is 1-n wherein n is an integer number). Also depicted in Figure 4 is the scCOz supply means, which include a CO2 reservoir (or tank) 24.1, a mass flow meter (MFM) 24.2, a CO2 pump 24.3; and a respective CO2 input valve 24.4 and CO2 output valve 24.5. It is relevant to note that the SCCO2 supply means may also include a (not shown) heat exchanger to guarantee that the CO2 remains in liquid sate before entering into the pump 24.3. The pump 24.3 being able to pressurize up to 60 MPa.

[0067] In one embodiment, the bioreactor is equipped with an advanced control system to ensure precise and efficient operation. The reactor includes an electronic data processor (not shown) configured to control and monitor the various components described above. This processor is designed to regulate key parameters such as pressure, temperature, and the temperature and quantity of oxygen / air flow, nutrient flow, anti-foam flow, pH adjustments, O2flow, scCO2flow, or combinations thereof. It oversees the operation of the solution reservoirs (or tanks), ensuring precise control of the flow and composition of solutions entering the reaction chamber. The electronic data processor is configured to receive input from the various components described above. It processes the collected data to determine the appropriate actions and subsequently controls the operation of valves, pumps, stirrers (17, 22), the volumetric actuator (19), among others. This integrated control system enhances the reactor's functionality, enabling precise adjustments to meet specific process requirements and ensuring consistent and reproducible results.

[0068] The innovative design of the bioreactor facilitates the application of cyclical pressure within the reaction chamber, providing significant advantages for decellularization, sterilization, drying, and recellularization of tissues. Cyclical pressure enhances the penetration of fluids and gases into the tissue matrix, ensuring thorough decellularization and efficient removal of cellular debris. This dynamic pressure control also promotes uniform sterilization by enabling deeper and more consistent exposure to sterilizing agents. During drying, cyclical pressure facilitates the removal of residual moisture, improving process efficiency and preserving tissue integrity. In recellularization, the cyclical pressure mimics physiological conditions, encouraging better cell adhesion, distribution, and growth throughout the tissue.

[0069] Figure 5 depicts an alternative embodiment for the solution supply means 23 wherein each one of the at least one solution reservoir (or tank) 23.1 has its own solution pump 24.2.

[0070] Figure 6 represents an embodiment of the present disclosure of multiple reaction chambers sharing the same scCCh supply means and / or the same solution supply means. By enabling multiple chambers to operate concurrently, the system significantly increases throughput, allowing for the simultaneous processing of multiple tissue samples, which can be in varying stages of cellular growth, differentiation, or maturation. Furthermore, the shared supply infrastructure reduces overall equipment costs, optimizes the utilization of scCO2and solutions, and minimizes energy consumption. This arrangement also facilitates scalability and flexibility, as additional chambers can be integrated into the system without the need for redundant supply components, thereby streamlining operations and improving efficiency for large-scale or high-demand applications.

[0071] In Figure 7, a generic schematic representation of the tissue processing within the bioreactor according to the present disclosure is depicted. A combined decellularization and sterilization of multiple tissues, from soft to hard tissues, such as tissues from pancreas or aorta is accomplished with the presently disclosed bioreactor. In Figure 7, reference number 25 represents a dECM (decellularized Extracellular Matrix) from a biological tissue / organ obtained by decellularization within the reactor chamberand 26 a rECM (recellularized Extracellular Matrix) translating into the artificial tissue / organ recellularized in the reactor chamber.

[0072] In an embodiment, the customized scCCh bioreactor allows for continuous decellularization and recellularization. One of the most important advancements in this reactor is the specially designed chamber which is able to run scCOz cycles in a continuous mode, alternating with washing cycles with water or other detergent-free solutions, without requiring opening or manipulation by external means that could lead to contamination. The washing step can be enhanced by incorporating ultrasonication, utilizing an ultrasound probe specifically designed to operate under high-pressure conditions. Another innovative feature of the reactor is its capability to facilitate flow perfusion, enabling the sequential decellularization and recellularization of an organ.

[0073] The use of an innocuous solvent, such as scCO2, to assist in the processing of biological tissue presents a significant advantage. Although scCO2 has a limited capability for the complete removal of biological content, it can significantly enhance the quality of decellularized ECM while reducing both the processing time and the complexity of current protocols.

[0074] The use of scCO2 applies the principles behind supercritical fluid extraction to the removal of cellular components from tissues. ScCO2 assisted-decellularization has the advantage of being able to reduce excessive decellularization times, even when used only to facilitate the rinsing of cytotoxic decellularization agents. Potentially, scCO2 can also be utilized in combination with more conventional decellularizing methods, decreasing the ECM exposure time, or allowing for the use of lower concentrations of detergents, for example, while maintaining decellularization effectiveness.

[0075] The ideal balance between the employment of scCO2 and washing cycles is determined according to the type and size of tissue to study. Typically, the decellularization processes always start by a cell lysis cycle which can be done using scCO2, and then following the washing steps to extract the residual cell components. After each of these steps the characterization of the DNA content is performed. At the end of the process this should be under the 50 ng / mg of dried tissue. There are endless possibilities of exploring parameters such as time, temperature, and / or pressure, as wellas combining scCO2 with a variety of cosolvents, which hold great promise for breakthroughs that will disrupt the current methodologies.

[0076] In respect to the washing cycles and co-solvents selection the goal is to use the least toxic and harsh chemicals. The main reason for utilizing scCO2 in combination with more conventional decellularizing methods, is to decrease the ECM exposure time, or allowing for the use of lower concentrations of detergents, while maintaining decellularization effectiveness.

[0077] While during the scCO2 phase the CO2 diffuses through the tissue and extracts mainly apolar molecules and promotes physical dislodging, during the washing cycles the physical removal continues to happen as a result of the flow perfusion.

[0078] In an embodiment, the reactor specifications have to take into consideration the possibility of high pressures (up to 60 Mpa) in the scCO2 mode.

[0079] The reactor enables monitoring of the decellularization process by detecting debris and DNA content in the washing solution. This ensures efficient removal of cellular components and allows for adjustments to washing cycles, resulting in a clean ECM suitable for recellularization or tissue engineering applications.

[0080] In one embodiment, the reactor features a modular design, consisting of multiple independent modules or chambers. These modules are capable of functioning simultaneously or individually, depending on the operational requirements. Additionally, the modular configuration allows for the easy removal, replacement, or reconfiguration of individual chambers without affecting the overall functionality of the reactor. This design provides flexibility and scalability, enabling the reactor to be customized and adapted for various processes and applications, enhancing its efficiency and versatility in fields such as tissue engineering and decellularization.

[0081] In an embodiment, the decellularization step is conducted within the same chamber or container and involves a CO2 pressurization module, along with systems for pressure regulation and CO2 flow control. Additionally, the module may include a CO2 recovery system to enhance efficiency and sustainability. This configuration is employedduring the decellularization phase, which typically lasts between one to three days per cell type, depending on the specific requirements of the process

[0082] In an embodiment, the washing step involves the use of water or other detergent-free solutions, applied through flow perfusion to ensure thorough cleaning. This process can be augmented by ultrasonication, utilizing an ultrasound probe specifically designed to operate under high-pressure conditions, further enhancing the efficiency and effectiveness of the washing procedure.

[0083] In an embodiment, the recellularization step incorporates an independent bioreaction control system, which manages critical parameters such as, but not limited to, oxygen / air flow, nutrient flow, anti-foam flow, pH adjustment, and oxygen monitoring through an 02 sensor. This phase typically can last one month and may extend further depending on the specific cellular requirements. Each cell requires a dedicated control system to maintain optimal conditions. The bioreactor control system can be configured as a single control channel within an individual box or as multiple channels housed in a single box, offering a space-saving and potentially more cost-effective solution.

[0084] The chamber is designed to function either as a supercritical extractor or as a bioreactor, featuring independent temperature control to accommodate various processes. Agitation within the chamber is preferably through magnetic agitation, however, alternative methods such as rocker or orbital may also be employed to suit specific operational requirements.

[0085] In this solution, the decellularization step, being relatively quick and lasting between 1 to 7 days, can be efficiently managed with 10 to 30 chambers, depending on the specific application and throughput requirements.

[0086] In the recellularization phase, which requires a minimum duration of 7 days, each chamber can be equipped with an independent bioreaction control system to ensure precise regulation of the conditions necessary for successful recellularization.

[0087] This configuration facilitates cost-effective scalability compared to independent units, while offering the added benefit of centralized software control. It is particularlywell-suited for both research and development applications and industrial-scale operations, providing flexibility and efficiency across various stages of implementation.

[0088] In one embodiment, the chambers are equipped with at least two windows positioned to allow both illumination and observation of the samples. The scCO2 module features precise control of pressurization and depressurization rates, with the capability to inject a co-solvent at any stage of the process. Decellularization is conducted in a continuous mode, alternating between exposing the tissue to scCO2 and a co-solvent (e.g., ethanol, water, TnBP, or others) and performing washing cycles with detergent-free solutions. Operational parameters such as temperature, pressure, exposure time, and depressurization rate are carefully adjusted based on cell removal efficiency and the preservation of tissue components. The scCO2 system operates in continuous flow mode to enhance the physical removal of cellular components, with CO2 being recycled for improved sustainability. To validate the reactor on the recellularization mode a new step to the process is introduced, to perfuse a cell suspension through the vasculature of dECM constructs and using dynamic seeding method. In the perfusion mode a pressure sensor ensures the integrity of the vasculature of the tissue during washing steps, and additional sensors, such as those for pH, CO2 / O2 levels, and anti-foaming, are integrated for precise monitoring and control of the process. In the third stage, to validate the reactor on the recellularization mode a new step to the process will be introduced, to perfuse a cell suspension through the tubular dECM constructs and using dynamic seeding method.

[0089] In another possible setting, the operational parameters can be adjusted to decellularize, sterilize and dry ECM with no further recellularization. As for the sterilization step, a specific mixture of co-solvents is used, if necessary (peracetic acid / hydrogen peroxide). Sterilized and dried dEMC can be obtained if moisture content is fully removed.

[0090] Figure 9 shows a schematic representation of an embodiment of a decellularization method. The method begins with the collection of the body region of a porcine pancreas 27, preferably corresponding to the central portion of the organ. The collected pancreatic tissue is then thawed by rinsing with antibiotic-supplementedphosphate-buffered saline PBS_Chl 28, thereby preparing the tissue for further processing while reducing the risk of microbial contamination. After thawing, the tissue is cut into standardized sections 29, allowing more homogeneous exposure of the samples to the decellularization agents and / or processing conditions. The sectioned tissue is subsequently subjected to cold incubation under agitation 30, preferably on ice, to promote washing and equilibration of the tissue before decellularization.

[0091] In an embodiment, the pancreatic tissue is decellularized using a traditional detergent-based decellularization protocol 31, thereby obtaining a traditional decellularized extracellular matrix T_dECM. In this protocol, the tissue sections are first subjected to an initial washing step with antibiotic-supplemented phosphate-buffered saline or antibiotic-supplemented ultrapure water 31.1. The samples are then treated with an anionic detergent, preferably 0.5% w / v sodium deoxycholate SDC, to promote disruption and removal of cellular membranes 31.2. This step is followed by treatment with a non-ionic detergent, preferably 0.1% v / v Triton X-100, to further assist in the solubilization and removal of residual cellular components 31.3. The tissue is then exposed to an enzymatic digestion step using DNase, preferably at 40 lU / mL, to degrade residual nucleic acids remaining within the extracellular matrix 31.4. A final washing step with antibiotic-supplemented phosphate-buffered saline or antibiotic-supplemented ultrapure water is then performed to remove residual detergents, enzymes, and cellular debris 31.5.

[0092] In an embodiment, the traditional detergent-based protocol 31 comprises five sequential cycles. Each cycle includes the steps of washing, detergent treatment, enzymatic digestion, and final washing, with the solutions being replaced at regular intervals. Preferably, each step is performed for about 1 hour under agitation, with the detergent and washing steps being carried out under cold conditions and the DNase step being carried out at about 37°C. In the first cycle, phosphate-buffered saline supplemented with antibiotic may be used as the washing medium, while in the following cycle ultrapure water supplemented with antibiotic may be used instead. This alternating washing pattern may be maintained throughout the five cycles. Samples may be collected at selected intermediate and final time points, for example after thesecond, fourth, and fifth cycles, to monitor the progression and efficiency of decellularization.

[0093] In an embodiment, the pancreatic tissue is decellularized using a supercritical carbon dioxide-based protocol 32, thereby obtaining a supercritical carbon dioxidederived decellularized extracellular matrix scCO2_dECM. In this protocol, standardized pancreatic tissue sections are first washed with phosphate-buffered saline before exposure to supercritical carbon dioxide 32.1. The washed tissue is then introduced into a supercritical carbon dioxide reactor and subjected to a supercritical CO2decellularization cycle 32.2. Preferably, the cycle is performed at a pressure of about 115-120 bar and a temperature of about 35-40°C for about 1 hour, followed by slow depressurization. These conditions allow penetration of the supercritical fluid into the tissue, promoting removal of cellular material while reducing the need for harsh chemical detergents.

[0094] In an embodiment, after each supercritical CO2exposure cycle, the pancreatic tissue sections are subjected to sequential post -treatment washing 32.3. Preferably, this washing comprises incubation with ultrapure water, antibiotic-supplemented phosphate-buffered saline, and phosphate-buffered saline, each under cold orbital agitation for about 1 hour. In one embodiment, the supercritical CO2-based protocol comprises six decellularization cycles, each followed by the post-treatment washing sequence. Samples may be collected after selected cycles, for example after the second, fourth, and sixth cycles, to evaluate the progression of tissue decellularization and preservation of the extracellular matrix.

[0095] In an embodiment, and following completion of either the traditional detergentbased protocol 31 or the supercritical carbon dioxide-based protocol 32, the resulting decellularized pancreatic samples are frozen, preferably at about -80°C, and subsequently freeze-dried. The freeze-dried decellularized matrices may then be stored or used for subsequent physicochemical, structural, biochemical, sterility, endotoxin, and / or biological analyses.

[0096] The efficiency of the decellularization protocols was evaluated using native and decellularized pancreatic tissue samples collected at different stages of the process.Residual DNA content was quantified to assess the removal of cellular material. For this purpose, dried samples were reduced into small fragments, subjected to DNA extraction, and the extracted DNA was quantified by ultraviolet-visible spectrophotometry. This analysis allowed the progression of decellularization to be monitored throughout the different processing cycles.

[0097] The preservation of extracellular matrix components was also evaluated in native and decellularized samples. Dried and milled tissue samples were used to quantify glycosaminoglycans, soluble collagen, and insoluble collagen. These analyses allowed assessment of the extent to which each decellularization protocol removed cellular material while maintaining relevant extracellular matrix constituents.

[0098] The structural preservation of the tissue was further assessed by histological analysis. Native and decellularized samples were fixed, dehydrated, embedded, sectioned, and stained to evaluate tissue architecture, nuclear material removal, collagen distribution, and collagen fiber organization. Stained sections were observed by light microscopy, and selected collagen-specific stained sections were additionally analysed under polarized light to assess collagen birefringence. Image analysis was performed to distinguish different collagen fiber populations based on colour segmentation, allowing calculation of the relative area of each fiber type.

[0099] The surface morphology of native and decellularized samples was evaluated by scanning electron microscopy. Freeze-dried samples were mounted on supports, coated with a conductive metallic layer, and observed under high magnification. This analysis enabled visualization of the matrix surface, pore formation, and overall extracellular matrix organization after decellularization.

[0100] The ultrastructure of native and decellularized samples was evaluated by transmission electron microscopy. Samples were chemically fixed, post -fixed, stained, dehydrated, embedded, and sectioned into ultrathin sections. The sections were then contrasted and imaged to assess fine structural features, including cellular remnants, collagen fiber organization, and preservation of the extracellular matrix network.

[0101] A proteomic analysis was also performed to characterize the protein composition of the decellularized matrices. In some cases, decellularized samples weresubjected to an additional washing step in sterile buffered solution under agitation at physiological temperature to reduce residual cellular debris associated with preliminary cytotoxic responses. Freeze-dried decellularized samples, with or without this additional washing step, were processed for protein extraction, enzymatic digestion, peptide separation, and mass spectrometry-based protein identification and quantification. The resulting data were analysed against a porcine protein database, and protein abundance was determined using label-free quantification.

[0102] Fourier-transform infrared spectroscopy was used as a complementary biochemical characterization method. Native tissue, decellularized samples, and additionally washed decellularized samples were analysed over a broad infrared spectral range. Spectra were obtained from multiple instrumental replicates, converted from transmittance to absorbance, normalized, and averaged for each experimental group. This analysis enabled comparison of the main biochemical signatures associated with lipids, proteins, collagen-related structures, and nucleic acid-associated components.

[0103] After decellularization, samples obtained by both protocols were sterilized using a supercritical carbon dioxide-based sterilization process. Freeze-dried samples were placed in sterilization bags and introduced into a sealed vessel containing a sterilizing solution and controlled humidity. The sterilization procedure comprised two supercritical carbon dioxide cycles: a first longer cycle for microbial inactivation and a second shorter cycle to assist removal of residual sterilizing agents. After processing, the samples were kept under extraction conditions to allow evaporation of remaining volatile residues before further use.

[0104] Sterilization efficiency was assessed by a turbidity assay using a bacterial biological indicator. Decellularized samples were inoculated with a defined bacterial load, allowed to dry, sealed, and subjected to the sterilization process. After sterilization, samples were transferred to culture medium and incubated under static conditions. Sterilized and non-sterilized samples, inoculated and non-inoculated controls, as well as positive and negative medium controls, were evaluated. Turbidity was monitored at different time points, with a clear medium indicating absence ofdetectable microbial growth and a turbid medium indicating survival or proliferation of viable microorganisms.

[0105] Endotoxin content was quantified in decellularized and sterilized pancreatic tissue samples to evaluate the ability of the combined decellularization and sterilization process to reduce pyrogenic contaminants. Samples were resuspended in endotoxin-free water and analysed using a chromogenic endotoxin assay. Absorbance was measured at the appropriate wavelength, allowing endotoxin levels to be determined and compared between experimental groups.

[0106] The biological safety of the decellularized matrices was evaluated using leachates obtained from freeze-dried and sterilized samples after an additional washing step. The samples were incubated in cell culture medium to obtain conditioned media, which were then supplemented, filtered, and used for in vitro testing. Immortalized human pancreatic cells were seeded in culture plates, allowed to adhere, and subsequently exposed to the conditioned media. Cell metabolic activity, proliferation, and morphology were evaluated after 24 hours, 72 hours, and 7 days of exposure.

[0107] Cell metabolic activity was assessed using a resazurin-based assay. At each time point, the culture medium was replaced with fresh medium containing the metabolic reagent, followed by incubation under standard cell culture conditions. Fluorescence was then measured to determine cellular metabolic activity in response to the different sample leachates.

[0108] Cell proliferation was evaluated using a nucleotide incorporation assay. Cells were incubated with the labelling solution at selected time points, fixed, and processed according to the assay procedure. Incorporated label was detected by colorimetric measurement, allowing comparison of proliferative activity between cells exposed to leachates from the different decellularized matrices and control conditions.

[0109] Cell morphology and cytoskeletal organization were assessed by fluorescence staining. At each time point, cells were fixed, permeabilized, blocked, and stained to visualize nuclei and actin filaments. Fluorescence microscopy was then used to assess cell morphology, cytoskeletal organization, and cell distribution overtime.

[0110] Statistical analysis was performed on the quantitative data obtained from the different assays. Results were expressed as mean values with standard deviation. Differences between experimental groups were assessed using appropriate analysis of variance and pairwise comparison tests when applicable. Statistical significance was considered for probability values equal to or below 0.05.

[0111] Figure 10 shows a graphical representations of an embodiment of biochemical characterization of native and decellularized porcine pancreatic tissue: DNA content and percentage reduction over time during traditional detergent-based and scCO2-based decellularization protocols (Fig. 10A); Sulfated glycosaminoglycan quantification in native tissue and decellularized pancreatic matrices (Fig. 10B); Soluble and insoluble collagen quantification in native tissue and decellularized pancreatic matrices (Fig. 10C).

[0112] Data is expressed as mean ± SD. Statistical significance was determined by oneway ANOVA for overall comparisons and unpaired t-test for comparisons between decellularized groups, with *p < 0.05, **p < 0.01, and ***p < 0.001.

[0113] As shown in Fig. 10A, both decellularization protocols promoted a marked and progressive reduction in DNA content over time. The traditional detergent-based protocol showed a faster initial decrease in DNA content, whereas the supercritical CO2-based protocol led to a more gradual reduction throughout the processing cycles. Nevertheless, both protocols achieved a final DNA reduction above 90%, reaching values below the commonly accepted threshold for effective tissue decellularization.

[0114] The preservation of key extracellular matrix components is shown in Fig. 10B and Fig. 10C. Sulfated glycosaminoglycan content was significantly reduced after both decellularization protocols when compared with native tissue, indicating that part of these matrix components was lost during processing. However, the supercritical CO2-derived matrix retained a significantly higher amount of sulfated glycosaminoglycans than the matrix obtained using the traditional detergent-based protocol.

[0115] Soluble collagen content was also significantly reduced in both decellularized groups relative to native tissue, with no significant differences between the two protocols. In contrast, insoluble collagen content was not significantly altered among native tissue and the two decellularized groups, suggesting that the main collagenousframework of the pancreatic extracellular matrix was broadly preserved after decellularization.

[0116] Fig. 11 shows graphical and microscopic representations of an embodiment of structural characterization of native and decellularized porcine pancreatic tissue: scanning electron microscopy micrographs of native tissue, traditional detergent-based decellularized matrix and scCO2-based decellularized matrix (Fig. 11A, panels a-c); transmission electron microscopy micrographs of native tissue, traditional detergentbased decellularized matrix and scCO2-based decellularized matrix (Fig. 11A, panels d-f); hematoxylin and eosin staining of native tissue, traditional detergent-based decellularized matrix and scCO2-based decellularized matrix (Fig. 11A, panels g-i); Masson's Trichrome staining of native tissue, traditional detergent-based decellularized matrix and scCO2-based decellularized matrix (Fig. 11A, panels j-l); Picrosirius Red staining of native tissue, traditional detergent-based decellularized matrix and scCO2-based decellularized matrix, with images acquired under polarized light and brightfield conditions (Fig. 11B, panels m-o); and quantitative analysis of collagen fiber distribution based on polarized light images (Fig. 11C).

[0117] Data is expressed as mean ± standard deviation. Statistical analysis was performed using two-way analysis of variance for overall comparison, wherein * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001.

[0118] SEM analysis revealed a dense structure with reduced internal porosity in native tissue, consistent with the presence of cellular components and compact tissue organization. In contrast, both decellularized matrices displayed a more porous and complex architecture, indicating the removal of cellular material and exposure of the extracellular matrix network. This porous structure was clearly observed in both T_dECM and scCO2_dECM samples.

[0119] TEM analysis supported the SEM observations. Native tissue presented a dense ultrastructure, with abundant cellular material and a compact collagen fibrillar network. After decellularization, both protocols resulted in a marked reduction of cellular content. T_dECM showed apparent complete removal of cellular material, whereas scCO2_dECM showed near-complete cellular elimination, with only occasional minimalresidual debris. Importantly, the collagen network appeared better preserved in scCO2_dECM than in T_dECM, suggesting that the scCO2-based protocol better maintained the ultrastructural organization of the extracellular matrix.

[0120] Histological staining further confirmed the removal of nuclear material and the preservation of extracellular matrix components. H&E staining showed a dense organization in native tissue, with cellular and matrix components closely intercalated. In both decellularized groups, no visible nuclei were observed, confirming effective decellularization. However, the matrix in T_dECM appeared less organized, while scCO2_dECM retained a more defined fibrillar structure. Masson's Trichrome staining showed that collagen fibers were less evident in native tissue due to masking by cellular content. After decellularization, collagen became more apparent, although T_dECM showed a fragmented collagen network, whereas scCO2_dECM displayed a more continuous blue-stained collagen structure with no observable nuclei or cytoplasmic staining.

[0121] Picrosirius Red staining further supported these observations and allowed the evaluation of collagen fiber organization under polarized light. Red / orange fibers, associated with thicker and more mature collagen type I, were predominant in all groups, whereas green / yellow fibers, associated with thinner and less organized collagen type III, represented a smaller fraction. Quantitative analysis showed that collagen type I represented approximately 74% of the fiber area in native tissue, 91% in T_dECM, and 89% in scCO2_dECM, while collagen type III represented approximately 26%, 9%, and 11%, respectively.

[0122] No statistically significant differences were observed between the two decellularized groups. However, native tissue showed a significantly lower relative collagen type I area and a correspondingly higher collagen type III area compared with both decellularized matrices. Overall, these results indicate that both protocols effectively removed cellular material, while scCO2-based decellularization better preserved the fibrillar extracellular matrix architecture.

[0123] Figure 12 shows graphical representations of an embodiment of biochemical and proteomic characterization of native and decellularized porcine pancreatic tissue:Fourier-transform infrared spectra of native tissue, traditional detergent-based decellularized matrix and scCO2-based decellularized matrix, including highlighted spectral regions corresponding to 3025-2850 cm-1, 1700-1180 cm-1and 1200-834 cm-1(Fig. 12A); and heatmaps showing the relative abundance, on a logloscale, of structural extracellular matrix-related proteins and pancreas-related functional proteins in traditional detergent-based and scCO2-based decellularized matrices (Fig. 12B).Structural proteins include interstitial fibrillar collagens, non-fibrillar collagens, basal membrane proteins, proteoglycans and small leucine-rich proteoglycans, while functional proteins include proteins involved in pancreatic secretion.

[0124] As shown in Fig. 12A, the FTIR spectra of native tissue, T_dECM and scCO2_dECM were generally comparable, indicating that the main biochemical features of the pancreatic matrix were preserved after both decellularization protocols. The 3025-2850 cm-1region, associated with CH2and CH3stretching vibrations and lipid-related structures, showed detectable bands in all groups, with no major differences in spectral profile between native and decellularized samples.

[0125] The 1700-1180 cm-1region, corresponding mainly to Amide I, II and III bands, was also well defined in all conditions. Since this region is associated with protein structures, including collagen, the comparable profile observed between groups suggests preservation of the main protein-based extracellular matrix components after decellularization. In contrast, the 1200-834 cm-1region, associated with phosphate groups and nucleic acid-related structures, showed higher absorbance in native tissue than in both decellularized matrices. The reduced intensity observed in T_dECM and scCO2_dECM supports the removal of nucleic acid-associated material and is consistent with the decellularization efficiency observed for both protocols.

[0126] Proteomic analysis, presented in Fig. 12B, further characterized the extracellular matrix composition of T_dECM and scCO2_dECM. The heatmaps showed distinct protein profiles between the two decellularization methods, indicating differences in matrix preservation and in the retention of tissue-related proteins. Structural extracellular matrix proteins detected included basal membrane proteins, proteoglycans and small leucine-rich proteoglycans, interstitial fibrillar collagens and non-fibrillar collagens.

[0127] Basal membrane proteins, including collagen IV isoforms, and selected proteoglycans or small leucine-rich proteoglycans, such as biglycan and asporin, were detected at low abundance and were mainly identified in T_dECM. Interstitial fibrillar collagens, including collagen I, II, III and V isoforms, were prominently detected in both decellularized matrices, supporting preservation of the main structural collagen network after both protocols. Non-fibrillar collagens, including collagen VI isoforms, were also detected in both groups, although with higher relative abundance in T_dECM.

[0128] Regarding pancreas-related functional proteins, proteins associated with pancreatic secretion were predominantly detected in scCO2_dECIVI and were not detected in T_dECM. This suggests that the scCO2-based protocol may better preserve selected tissue-specific biochemical features of pancreatic origin, while both protocols maintained relevant structural extracellular matrix proteins. Overall, the FTIR and proteomic results indicate that both decellularization approaches preserved the major biochemical matrix profile, with scCO2_dECM showing improved retention of pancreas-related functional protein signatures.

[0129] Figure 13 shows graphical representations of an embodiment of sterilization validation and endotoxin quantification of decellularized porcine pancreatic matrices: turbidity assay results showing the presence of bacterial growth, represented by a check mark, or absence of bacterial growth, represented by a cross, in sterilized and nonsterilized inoculated samples of traditional detergent-based decellularized matrix and scCO2-based decellularized matrix over 24 hours, 48 hours, 72 hours and 7 days (Fig.13A); and endotoxin quantification in sterilized traditional detergent-based and scCO2-based decellularized matrices, expressed as endotoxin units per milligram of dry weight (Fig. 13B). Statistical significance is indicated as *** for p < 0.001.

[0130] Sterilization efficacy was evaluated by a turbidity assay performed on both T_dECM and scCO2_dECIVI samples, using B. subtilis as a biological indicator organism. As shown in Fig. 13A, the culture medium from inoculated and sterilized samples remained non-turbid throughout the 7-day incubation period, indicating absence of detectable bacterial growth. In contrast, the inoculated and non-sterilized samples became turbid within 24 hours, confirming bacterial proliferation in the absence ofsterilization. These results indicate that the sterilization process was effective for both decellularized matrices.

[0131] The assay controls further supported the validity of the sterilization assessment. Non-inoculated sterilized samples remained clear at all evaluated time points, confirming the absence of detectable contamination after processing. Non-inoculated and non-sterilized samples showed turbidity only at the later time point, suggesting delayed contamination, potentially associated with residual microbial presence or external contamination. As expected, the inoculated culture medium used as positive control became turbid, while the non-inoculated culture medium used as negative control remained clear.

[0132] Endotoxin content was also assessed to evaluate the presence of pyrogenic residues in the sterilized decellularized matrices. As shown in Fig. 13B, scCO2_dECM exhibited markedly lower endotoxin levels than T_dECM, with values of approximately 0.027 EU / mg dry weight and 0.413 EU / mg dry weight, respectively. This significant reduction indicates that the scCO2-based protocol was more effective in limiting or removing endotoxin contamination, supporting the production of a cleaner and potentially safer decellularized pancreatic matrix.

[0133] Figure 14 shows graphical and microscopic representations of an embodiment of in vitro biological assessment of decellularized porcine pancreatic matrices: cell metabolic activity of T0158-Myc cells cultured with leachates obtained from traditional detergent-based decellularized matrix, scCO2-based decellularized matrix and control medium, assessed after 24 hours, 72 hours and 7 days (Fig. 14A); cell proliferation of T0158-Myc cells cultured under the same conditions, assessed after 24 hours, 72 hours and 7 days (Fig. 14B); and representative fluorescence microscopy images of T0158-Myc cells exposed to the respective leachates or control medium, showing nuclei staining and actin cytoskeleton staining after 24 hours, 72 hours and 7 days (Fig. 14C).

[0134] As shown in Fig. 14A, cell metabolic activity increased progressively over time in all tested groups, including cells exposed to T_dECM leachates, scCO2_dECM leachates, and control medium. At all evaluated time points, namely 24 hours, 72 hours, and 7 days, cell metabolic activity remained above the 70% viability threshold, indicating thatneither decellularized matrix induced cytotoxic effects. No statistically significant differences were observed between experimental conditions at any time point.

[0135] Cell proliferation followed a similar trend, as shown in Fig. 14B. BrdU incorporation increased over time in all groups, confirming progressive cell proliferation during the culture period. Cells exposed to leachates from both T_dECM and scCO2_dECM showed proliferation levels comparable to the control condition, with no statistically significant differences between the two decellularization protocols or relative to the control. These results indicate that soluble compounds released from both matrices did not impair cellular proliferation.

[0136] Fluorescence microscopy further supported these findings. As shown in Fig. 14C, T0158-Myc cells maintained their typical morphology and displayed a well-defined actin cytoskeleton across all experimental conditions and time points. Nuclei staining also showed a progressive increase in cell density from 24 hours to 7 days, corroborating the metabolic activity and proliferation results. Overall, these data indicate that both T_dECM and scCO2_dECM leachates are cytocompatible and support cell viability, proliferation, and preserved cellular morphology.

[0137] Both the traditional detergent-based protocol and the supercritical carbon dioxide-based protocol effectively removed cellular material, achieving residual DNA levels below the accepted decellularization threshold of 50 ng / mg dry tissue, while maintaining the overall extracellular matrix structure.

[0138] Although both approaches were effective, the supercritical carbon dioxide-based protocol showed advantages in extracellular matrix preservation. This protocol better maintained the fibrillar architecture of the pancreatic matrix, retained higher levels of sulphated glycosaminoglycans, and preserved pancreas-related proteins associated with tissue-specific biochemical identity. These features suggest that supercritical carbon dioxide enables a milder decellularization process, reducing matrix disruption while still ensuring efficient cellular material removal.

[0139] The supercritical carbon dioxide-based approach also resulted in significantly lower endotoxin levels and enabled effective sterilization of the decellularized matrices.This supports its potential use as an integrated processing strategy, combining decellularization and sterilization within a cleaner and more controlled workflow.

[0140] Overall, supercritical carbon dioxide represents a sustainable alternative to conventional detergent-based decellularization methods for producing decellularized pancreatic extracellular matrices. By offering an improved balance between cellular removal, extracellular matrix preservation, sterility, reduced pyrogenic contamination, and cytocompatibility, this approach may contribute to the development of safer and more biologically relevant pancreatic-derived biomaterials for regenerative medicine and tissue engineering applications.

[0141] The term "comprising" whenever used in this document is intended to indicate the presence of stated features, integers, steps, components, but not to preclude the presence or addition of one or more other features, integers, steps, components or groups thereof. The disclosure should not be seen in any way restricted to the embodiments described and a person with ordinary skill in the art will foresee many possibilities to modifications thereof. The above-described embodiments are combinable. The following claims further set out particular embodiments of the disclosure.

[0142] It follows some examples of practical applications of the reactor: decellularization of hard tissues, such as bone, cartilage or meniscus, and soft tissues such as vascular tissue, skin, pancreas or heart, to ensure complete removal of cellular material; examples are processing of the meniscus using alternating pressure cycles to preserve its fibrocartilaginous structure and decellularization of the aorta, maintaining its elastic and functional properties for use in vascular grafts.

[0143] The examples below provide detailed operational parameters, including specific pressure and temperature ranges, exposure times, and co-solvent usage, illustrating the reactor's versatility and adaptability to various tissue types and decellularization processes.Example 1 - production of bone type tissuePressure range: 80-400 barTemperature range: 32-60 °CExposure time: 1-3 hCo-solvent used: ethanol, or othersExample 2 - described production of aorta type tissuePressure range: 80-400 barTemperature range: 32-40 °CExposure time: 1-3 hCo-solvent used: ethanol, or others.Example 3 - described production of meniscus type tissuePressure range: 80-400 barTemperature range: 32-40 °CExposure time: 1-3 hCo-solvent used: ethanol, or others.

[0144] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and / or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It is also to be understood that unless otherwise indicated or otherwise evident from the context and / or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

[0145] The disclosure should not be seen in any way restricted to the embodiments described and a person with ordinary skill in the art will foresee many possibilities to modifications thereof.

[0146] The above-described embodiments are combinable.

[0147] The following claims further set out particular embodiments of the disclosure.

Claims

C L A I M S1. A bioreactor for artificial tissue or organ production, comprising:at least one reaction chamber (6) arranged to receive and process a tissue (12); at least one fluid inlet (18) and at least one fluid outlet (11) connected to the reaction chamber for inflow and outflow of fluids;at least one door (8) for facilitating the placement of the tissue inside the reaction chamber;supercritical CO2 supply means (24) connected to the at least one fluid inlet (18) and the at least on fluid outlet (11) for supplying supercritical CO2 in the reaction chamber for decellularization of the tissue;solution supply means (23) connected to the at least one fluid inlet (18) and the at least on fluid outlet (11), wherein the solution supply means (23) is configured to supply a culture medium, and / or a cell inoculum in the reaction chamber for recellularization of the tissue;an electronic data processor configured to control and monitor the solution supply means (23) and the supercritical CO2 supply means (24) allowing decellularization, sterilization, and recellularization of the tissue to obtain an artificial tissue or organ.

2. The bioreactor according to the previous claim, wherein the solution supply system (23) is further configured for decellularization of the tissue in the reaction chamber (6) by supplying at least one of the following solutions: a decellularization solution, or a combination thereof; preferably ultrapure water, an enzymatic solution, a detergent solution, an acid or alkaline solution, a chelating agent solution supercritical CO2 or a combination thereof.

3. The bioreactor according to any of the previous claims, wherein the solution supply system (23) is further configured for sterilization of the tissue in the reaction chamber (6) by supplying at least one of the following solutions: a sterilization solution, or a combination thereof; preferably ethanol, isopropanol, peracetic acidsolution, hydrogen peroxide solution, antibiotic and / or antimycotic solution, supercritical CO2 combined with a sterilizing additive, or a combination thereof.

4. The bioreactor according to any of the previous claims further comprising drying means for removing residual moisture and solvents from the tissue.

5. The bioreactor according to any of the previous claims, wherein the solution supply system (23) is configured for recellularization of the tissue by supplying at least one of the following solutions: a cell suspension, a hydrogel containing cells, a growth medium, a differentiation medium, cell spheroids, cell organoids or a combination thereof to the interior of the reaction chamber (6).

6. The bioreactor according to any of the previous claims further comprising a residue outlet for discharging cellular debris, chemical residues, and byproducts generated during decellularization, sterilization, drying and / or recellularization; preferably wherein the residue outlet is operatively connected to a filtration system for facilitating efficient removal and preventing contamination.

7. The bioreactor according to any of the previous claims further comprising:a CO2 reservoir (24.1) and;a CO2 pump (24.3) arranged to compress liquid CO2 into a supercritical state for pressurizing the reaction chamber and facilitating the removal of biological content from the tissue (12) content.

8. The bioreactor according to the previous claim, wherein the supercritical CO2 supply means (24) further comprise a CO2 input valve (24.4) and CChoutput valve (24.5) for controlling inflow and outflow of supercritical CChto the interior of the reaction chamber.

9. The bioreactor according to any of the previous claims 6 or 7, wherein the supercritical CO2 supply means (24) comprise a mass flow meter (24.2) for measuring and control of supercritical CO2 entering the CO2 pump (24.3).

10. The bioreactor according to any of the previous claims further comprising:at least one solution reservoir (23.3), preferably 2, 3, 4 or 5 solution reservoirs; and a solution pump (23.2) for circulating a solution between said at least one solution reservoir and an interior of the reaction chamber.

11. The bioreactor according to the previous claim, wherein each of the at least one solution reservoir (23.3) of the solution supply means (23) further comprises a solution input valve (23.3) and a solution output valve (23.4) for controlling inflow and outflow of solution to the interior of the reaction chamber.

12. The bioreactor according to any of the previous claims further comprising heating means (16) surrounding a main body of the reaction chamber, wherein said heating means are configured to regulate and maintain the temperature inside the reaction chamber.

13. The bioreactor according to any of the previous claims further comprising a temperature probe (7) for measuring temperature in the interior of the reaction chamber.

14. The bioreactor according to any of the previous claims wherein, a rotative stirrer (17) is placed under a tissue support (15) wherein the tissue (12) is placed upon said tissue support (15); wherein the rotative stirrer is arranged for promoting mass changes between tissue cells.

15. The bioreactor according to any of the previous claims, further comprising a volumetric stirrer (22) fluidical ly connected to the outlet fluid connection (11) and to the inlet fluid connection (18); and configured to displace the solution within the reaction chamber in one direction or the opposite.

16. The bioreactor according to any the previous claims, further comprising a back pressure regulator (21) operatively connected to the at least one outlet fluidconnection (11) for controlling a maximum pressure in the interior of the reaction chamber.

17. The bioreactor according to the previous claim wherein the electronic data processor is configured to regulate the back pressure regulator (21), preferably for setting a maximum allowable pressure within the reaction chamber.

18. The bioreactor according to any the previous claims, further comprising a one-way valve (20) operatively connected to the at least one inlet fluid connection (18) for preventing back-flow of fluids going into the interior of the reaction chamber.

19. The bioreactor according to the previous claim, further comprising a volumetric actuator (19) operatively connected to the input fluid connection (18) upstream of the one-way valve (20), for allowing pressure changes within the interior of the reaction chamber.

20. The according to the previous claim, wherein the electronic data processor is configured to control an internal volume of the volumetric actuator (19) for allowing pressure changes within the interior of the reaction chamber.

21. The bioreactor according to any of the previous claims, further comprising a perfusion port (13) for accommodating the insertion of a needle or syringe for direct access to the tissue; preferably the perfusion port (13) further comprising a ball valve (14) for enabling rapid access and re-pressurization of the reaction chamber.

22. The bioreactor according to any of the previous claims, wherein the bioreactor comprises a plurality of reaction chambers (6) wherein each reaction chamber comprises its own solution supply means (23) to avoid cross-contamination between chambers; preferably 2, 3, 4, 5 reaction chambers.

23. The bioreactor according to any of the previous claims, further comprising at least one of the following sensors: temperature sensor, nutrient sensor, pressure sensor,flow sensor, anti-foam sensor, pH sensor, O2 sensor, CO2sensor, or combinations thereof.

24. A method of operating a bioreactor for artificial tissue or organ production according to any of the previous claims, comprising the following steps: introducing the tissue (12) into the at least one reaction chamber (6); supplying supercritical CO2and / or at least one decellularization solution into the interior of the reaction chamber (6) for decel lu la rizing the biological content of the tissue (12) in other to obtain a scaffold;introducing a sterilization solution in the reaction chamber for ensuring the elimination of contaminants before recellularization;feeding the reaction chamber (6) with a cell inoculum and a culture medium for the recellularization of the scaffold and generate an artificial tissue or organ.

25. The method according to the previous claim, further comprising the step of removing excess material from the reaction chamber (6) after decellularization, sterilization, drying and / or recellularization, wherein the excess material includes residual cellular debris, unreacted solutions, and / or processing byproducts.

26. The method according to any of the previous claims, further comprising the step of drying the scaffold after decellularization, sterilization, drying and / or recellularization.